Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease

Qutob, Haitham MohammedHabib; Saad, Ramadan A.; Bali, Hamza; Osailan, Abdulaziz; Jaber, Jumana; Alzahrani, Emad; Alyami, Jamilah; Elsayed, Hani; Alserihi, Raed; Shaikhomar, Osama A.

doi:10.1016/j.medcle.2022.02.029

Cited by 1 publication

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…USFDA granted EUA for tocilizumab to use on COVID-19 hospitalized adults and pediatric patients (2 years and above). This shows that the efficacy of the drug might gain good market and production facilities [55,56] . The monoclonal drug market continues to dominate in North America, Europe, Asia Pacific, Africa, and the Middle East and Latin American countries.…”

Section: Market Statusmentioning

confidence: 91%

See 1 more Smart Citation

Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics

Kotra¹,

Mallem²,

Kanuri³

et al. 2022

Prog Micobes Mol Biol

View full text Add to dashboard Cite

Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and chemotherapeutics against COVID-19 and its variants as well as the product specifications and marketing dynamics of its pharmacotherapies. There are several chemotherapeutics that have been studied for the treatment of COVID-19, including Paxlovid (Nirmatrelvir & Ritonavir) fixed dose combination, nirmatrelvir and ritonavir fixed dose combination, Remdesivir (Vekulary/Covifor) fixed dose combination, chloroquine and hydroxychloroquine, molnupiravir, favipiravir, Infliximab (Remsima®) fixed dose combination tocilizumab (Actimera), casirivimab+imdevimab (Ronapreve) fixed dose combination, ivermectin, methylprednisole. These drugs have been repurposed for use in COVID-19 due to their antiviral properties and ability to reduce inflammation. The COVID-19 death cases have significantly reduced because of tested efficacy of advanced biotherapeutics and chemotherapeutics. As for marketing dynamics, the demand for chemotherapeutics for the treatment of COVID-19 has increased significantly since the outbreak of the pandemic. Hence, the prices of anti-viral and monoclonal antibodies in top COVID-19 affected countries is also presented here. Considering the molecular interactions, therapeutic activity, efficacy, and adverse effects, the USFDA and the WHO recommended the aforementioned drugs. The chances of approval seems favouring biotherapeutics as these have the best characteristics among the chemotherapeutics. Overall, this review contributes to the scientific understanding of the COVID-19. This can help to inform future research and development efforts and contribute to the overall advancement of knowledge in the field of medicine.

show abstract

Section: Market Statusmentioning

confidence: 91%

“…Since the drug is to be given along with other immune-suppressant medicines under medical supervision, the cost of hospitalization will have added effect on the patient economic conditions. Hence, the drug maker Roche needs to consider making the drug in a generic version immediately to offer LMI countries [55,56] . 4.9.…”

Section: Market Statusmentioning

confidence: 99%